Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
Date:8/8/2011

release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the leadership and experience that Dr. Tursi will bring to the position of Chief Medical Officer; products in development for Dupuytren's contracture, Peyronie's disease, and Frozen Shoulder syndrome; and the potential for XIAFLEX to be used in multiple indications.  

Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.

A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended June 30, 2011, which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.

CONTACT:
James E. Fickenscher
Chief Financial Officer, Auxilium Pharmaceuticals, Inc.
+1-484-321-5900
jfickenscher@auxilium.com
or
William Q. Sargent Jr.
Vice-President, Investor Relations and Corporate Communications
+1-484-321-5900
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... announced the appointment of Joann V. Lofgren ... Market Development, effective July 6, 2015. In this role, ... executing on the company,s market and product development strategy ... to welcome Joann to the OncoSec team and have ...
(Date:7/5/2015)... TOKYO , July 6, 2015 ... first international symposium on Medical-Engineering Collaboration "Medicine ... on July 10, 2015 in Tokyo, ... or its medical applied research will present their ... technology and a new industry produced with 8K ...
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... MATEO, Calif., Feb. 28, 2011 Nile Therapeutics, Inc. ... the development of novel therapeutics for heart failure patients, ... MDT ) on the clinical development of ... failure and renal disease applications. "We are ...
... 2011 Hotspur Technologies announced today that Dr. ... clinical use of its Keeper™ Embolectomy Catheter.  The ... within arteries, while also incorporating the capability of ... The Keeper Catheter combines a compliant ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... 100% of all acids, chemicals and impurities; it also properly mineralizes the water ... it contains harmful contaminants.  These harmful contaminants are a byproduct of how the ...
(Date:7/6/2015)... ... July 06, 2015 , ... In ... medicine, the American Orthopaedic Society for Sports Medicine ( AOSSM ) will present ... Orlando, FL. As a leader in orthopaedic sports medicine, AOSSM annually provides ...
(Date:7/6/2015)... ... 06, 2015 , ... Acara Partners, a leading business team ... its complimentary educational webinar series for the summer of 2015. ... their clients through targeted marketing, sales, digital communications, branding and business development programs. ...
(Date:7/6/2015)... ... ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value of more ... of over 3.2 percent in the years to come to hit the USD 6.9 ... an anticipated launch of a number of promising pipeline candidates and an increase in ...
(Date:7/6/2015)... ... ... doTERRA, the leading global essential oils company, is pleased to announce the ... position as Director of the Hinckley Institute at the University of Utah, a position ... states that he was ready for a new challenge, and out of many potential ...
Breaking Medicine News(10 mins):Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4
... CHICAGO, July 8 The Hispanic ... its 75 city tour, including the top 10,Hispanic cities, to ... The tour recently cruised through Chicago hosting free,events to encourage ... well,with nature,s wellness drink: milk. , ...
... ... Can Promote Prostate Health , ... Jacksonville, Fla. (Vocus) July 8, 2009 -- On June 30th, the ... effectiveness" research. Among the 100 different questions posed, high on the list was ...
... , WEDNESDAY, July 8 (HealthDay News) -- Though researchers aren,t ... longer, they hope a drug used to prevent rejection of ... , Middle-age mice that were given the drug rapamycin (Sirolimus) ... didn,t get the drug. , The findings, disclosed in a ...
... , WASHINGTON and EVANSTON, Ill., July 8 ... a data integration partnership facilitating integration of a ... SimCapture(R). SimCapture is an all-in-one solution for capturing, ... encounters. Mentice, manufacturer of the Mentice VIST(TM) endovascular ...
... patients rely on drugs to prevent graft rejection, ... The class of immunosuppressive drugs known as calcineurin ... patients, kidneys and lead to high blood pressure, ... can effectively replace calcineurin inhibitors in preventing graft ...
... SAN FRANCISCO, July 8 For the third ... one of the top medical groups in California as measured ... is the nation,s largest professional organization of physician groups practicing ... as being one of the best medical groups in California ...
Cached Medicine News:Health News:The Hispanic got milk? Campaign Visits Chicago from July 2 - July 10 2Health News:'Comparative Effectiveness' Research Addresses Options for Treating Prostate Cancer 2Health News:'Easter Island' Drug Adds Years to Mice 2Health News:B-Line Medical(R) and Mentice, Inc. Announce Data Integration Partnership 2Health News:B-Line Medical(R) and Mentice, Inc. Announce Data Integration Partnership 3Health News:Post-transplant combo can replace toxic immune-suppressing drugs in monkeys 2
Round solid 15 mm wide lower plate. Open upper plate with inside diameter 12 mm. Serrated handle with locking thumb screw and polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
The popular E2002 Utrata Capsulorhexis Forceps with fine angled sharp tips. Angled 12 mm shafts with an iris stop. Flat handle with dull finish....
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Medicine Products: